Abstract | BACKGROUND: METHODS: Serum levels of mesothelin and CA125 were determined by commercially available assays in 117 samples obtained at diagnosis from patients with pleural malignant mesothelioma, 33 healthy, asbestos-exposed individuals, 53 patients with asbestos-related lung or pleural disease, and 30 patients presenting with benign pleural effusions. Cross-validated sensitivities were determined, and receiver operator characteristic curves were generated to compare the diagnostic accuracy of the biomarkers. RESULTS: CONCLUSION: Combining mesothelin and CA125 data does not improve the sensitivity of mesothelioma diagnosis over mesothelin alone. The use of both markers potentially increases the number of patients who can be monitored.
|
Authors | Jenette Creaney, Ivonne van Bruggen, Michelle Hof, Amanda Segal, Arthur W Musk, Nick de Klerk, Nora Horick, Steven J Skates, Bruce W S Robinson |
Journal | Chest
(Chest)
Vol. 132
Issue 4
Pg. 1239-46
(Oct 2007)
ISSN: 0012-3692 [Print] United States |
PMID | 17646232
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- CA-125 Antigen
- GPI-Linked Proteins
- Membrane Glycoproteins
- Mesothelin
|
Topics |
- Aged
- Biomarkers, Tumor
(blood, metabolism)
- CA-125 Antigen
(blood, metabolism)
- Female
- GPI-Linked Proteins
- Humans
- Immunohistochemistry
- Male
- Membrane Glycoproteins
(blood, metabolism)
- Mesothelin
- Mesothelioma
(diagnosis)
- Middle Aged
- ROC Curve
- Sensitivity and Specificity
- Tissue Distribution
|